Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Azitra, Inc. (AZTR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, which are central to understanding this clinical stage biopharmaceutical issuer focused on precision dermatology. Through its Forms 8-K, S-1, DEF 14A and related documents, Azitra outlines the status of its live biotherapeutic and engineered protein programs, capital structure, and stock exchange compliance.
Filings such as Form 8-K detail material events, including notices from NYSE American regarding non-compliance with minimum stockholders’ equity requirements and subsequent acceptance of Azitra’s plan to regain compliance by April 1, 2027. Other 8-K reports describe private placement transactions involving common stock, pre-funded warrants, and common stock purchase warrants, as well as placement agency agreements and registration rights agreements tied to these financings. Additional 8-Ks furnish quarterly financial results and discuss reverse stock split actions implemented through amendments to the company’s certificate of incorporation.
Azitra’s Form S-1 registration statements provide further insight into its equity line of credit with Alumni Capital LP, the potential issuance of ELOC shares and warrants, and the resale registration of securities issued in private transactions. These documents explain how the company may raise capital over time and the number and types of securities that may be issued. The DEF 14A definitive proxy statement for a Special Meeting of Stockholders describes proposals to approve share issuances under NYSE American rules, including shares underlying warrants issued pursuant to a securities purchase agreement.
On this page, Stock Titan pairs Azitra’s real-time EDGAR filings feed with AI-powered summaries that help explain the significance of key documents. Users can quickly understand stock issuance proposals, listing standard issues, reverse stock splits, and financing structures without reading every page of each filing. Access to forms related to insider or major holder transactions, when filed, complements this view by showing how ownership and capital structure evolve as Azitra advances its ATR-12, ATR-04, and ATR-01 programs.
Azitra, Inc. is asking stockholders at its virtual June 4, 2026 annual meeting to approve several major capital structure changes and routine governance items. Stockholders will elect four directors, including CEO Francisco D. Salva and COO Travis Whitfill, and vote on ratifying Grassi & Co., CPAs, P.C. as auditor for 2026.
The company seeks to amend its charter to increase authorized common stock from 200,000,000 to 750,000,000 shares, citing forecasted capital-raising needs to fund product development and other uses. As of April 24, 2026, 16,192,438 shares of common stock were outstanding, with a very large number of additional shares reserved, primarily for warrants.
Azitra also requests authority for the Board to implement one or more reverse stock splits at a ratio between 1-for-2 and 1-for-30 to help support compliance with NYSE American listing requirements. Additional proposals seek NYSE American–required approval for potential issuances of more than 19.99% of outstanding shares under a 2025 Alumni Capital LP agreement and a March 18, 2026 financing involving Series A Preferred Stock and Series B and C Warrants, plus an amendment and restatement of the 2023 Stock Incentive Plan to increase its share reserve and permission to adjourn the meeting if more votes are needed.
Azitra, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 4, 2026. The proxy seeks approval for nine proposals, including an amendment to increase authorized common shares from 200,000,000 to 750,000,000, shareholder authorization enabling the Board to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-30, approval related to issuances exceeding 19.99% under two recent securities purchase agreements, an amendment to increase the 2023 Stock Incentive Plan reserve, election of four directors, and ratification of the independent auditor. Shares outstanding were 16,192,438 as of April 24, 2026.
Azitra, Inc. Chief Financial Officer Norm Staskey received a grant of 35,524 stock options to buy common shares. The options have an exercise price of $0.2127 per share and expire on April 20, 2036. After this grant, Staskey holds 35,524 options directly.
One third of the options will vest on the one-year anniversary of the grant date, and the remaining two thirds will vest in equal monthly installments over the following two years. This is a compensation-related award rather than an open-market purchase or sale.
Azitra, Inc. reported that President and CEO Francisco D. Salva received a grant of stock options covering 220,879 shares of common stock. The options have an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options vest on the one-year anniversary of the grant date, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Salva directly holds options for 220,879 underlying shares.
Azitra, Inc. reported that Chief Operating Officer Travis Whitfill received a grant of stock options covering 64,300 shares of common stock. The options carry an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options will vest on the one-year anniversary of the grant date, and the remaining two-thirds will vest in equal monthly installments over the following two years. After this grant, Whitfill holds 64,300 stock options directly.
Azitra, Inc. has completed a private PIPE financing that can provide up to approximately $31.4 million, including initial gross proceeds of about $10.5 million from the sale of 10,485 shares of Series A convertible non-redeemable preferred stock bundled with warrants.
Each preferred share is paired with Series B and Series C warrants, each initially exercisable at $0.123 per share. After stockholder approval of additional authorized common shares and the related NYSE American requirements, each preferred share will automatically convert into roughly 8,128.1 common shares, subject to beneficial ownership caps of 4.99%, 9.99% or 19.99% per holder, with excess delivered as pre-funded warrants.
The Series B warrants become exercisable after stockholder approval and terminate 18 months later, while Series C warrants remain exercisable until 30 days after Azitra publicly reports data from its cosmetic filaggrin human study, with a potential 30-day extension and exercise price reset if the stock trades below the original strike. A registration rights agreement requires Azitra to file a resale registration statement within 45 days of closing, with liquidated damages of 1% of each investor’s purchase amount per 30 days if key registration milestones are missed. Azitra plans to use the initial net proceeds, together with existing cash, for research and development, general corporate purposes and working capital.
Azitra, Inc. President and CEO Francisco D. Salva reported significant insider purchases of derivative securities. On March 18, 2026, he bought 500 shares of Series A Convertible Non-Redeemable Preferred Stock, which has a stated value of $1,000 per share and automatically converts into 8,128.1 shares of common stock per preferred share once specific stockholder approvals and a charter amendment are obtained.
He also purchased 4,064,050 Series B Warrants and 4,064,050 Series C Warrants, each exercisable for common stock at $0.123 per share. The Series B Warrants become exercisable upon stockholder approval and expire 18 months afterward, while the Series C Warrants become exercisable upon stockholder approval and terminate 30 days after Azitra publicly announces data from its planned human cosmetic study using filaggrin technology.
Azitra, Inc. received a notice from NYSE American that it is not in compliance with the exchange’s continued listing standard requiring stockholders’ equity of at least $6.0 million for companies with losses in their five most recent fiscal years. As of December 31, 2025, Azitra reported stockholders’ equity of $3.8 million and losses over that five-year period. The exchange has accepted a previously submitted plan giving Azitra until April 1, 2027 to regain compliance with both the $4.0 million and $6.0 million equity thresholds, during which the company must provide quarterly progress updates. If it fails to make sufficient progress or meet these standards by the deadline, NYSE American staff may initiate delisting proceedings, though Azitra could appeal. The company also highlights that its latest audited financial statements contain an auditor’s paragraph expressing substantial doubt about its ability to continue as a going concern. Trading of Azitra’s common stock continues on NYSE American for now.
Azitra, Inc. canceled its 2026 special meeting of stockholders. The meeting was originally scheduled for February 6, 2026 and adjourned to March 6, 2026 after the company previously lacked a quorum. On March 4, 2026, Azitra withdrew the proposals described in its definitive proxy statement and decided not to reconvene the adjourned meeting.
Azitra is a clinical stage biopharmaceutical company focused on precision dermatology. Its lead program, ATR-12, is an engineered strain of S. epidermidis for Netherton syndrome and includes a Phase 1b trial in adult patients. A second program, ATR-04, targets EGFR inhibitor–associated rash and has FDA Fast Track designation and an open IND.